Company profile
Home - Nebuflow
Nebu~Flow Transforming Respiratory Drug Delivery. Developing the next generation of nebulisers enabling delivery of life changing treatments.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
SH01 | Transaction MzQ0MjA0ODYyMmFkaXF6a2N4
Published 05 Nov 2024 01:48
AA | Transaction MzQ0MTkwNjc0M2FkaXF6a2N4
Published 04 Nov 2024 02:55
AP01 | Transaction MzQ0MDgzOTA4OGFkaXF6a2N4
Published 24 Oct 2024 12:38
Company registered at Companies House
1 Apr 2024 to 31 Mar 2026
Acu-Flow is unlocking the delivery of the next generation of inhaled drugs for patients with respiratory disorders. According to the World Health Organisation, respiratory diseases (e.g. asthma/chronic obstructive pulmonary disorders (COPD)) are the leading causes of death and disability in the world. In the UK, the British Lung Foundation estimates 1 in ...
1 May 2022 to 30 Apr 2024
Acu-Flow is developing a new nebuliser device to enable inhalation for precise and efficient delivery of medicines to the lungs. According to the World Health Organisation, respiratory diseases (e.g. asthma and chronic obstructive pulmonary disorders) are the leading causes of death and disability in the world. In the UK, the British Lung Foundation estim...
1 Oct 2020 to 31 Aug 2021
Acu-Flow will develop a new, unique innovative functionality for its new nebuliser platform to enable inhalation delivery of liquid formulations for the precision delivery of medicines to the lungs. According to the World Health Organisation, respiratory diseases are known as the leading causes of death and disability in the world, with an estimated clini...
